Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
reads well ?
Further comparisons of the pharmacokinetic parameters of risperidone and 9-hydroxyrisperidone in plasma of patients administered VAL401 and the corresponding parameters obtained from published data for conventionally formulated risperidone provide evidence for altered biological processing of VAL401 as compared to risperidone
all its done is shown a "difference" between Risperidone and VAL401 and that its safe to use
so ?
Thanks Team Reads well for 401 to my untrained eye!
Not high and mighty, BUSY.... and think there are quite a few more pages, to type... ? Still think what you wish !
Here you go Uncanny...…..seeing as ValJu is being his/her usual high and mighty>>>
Background and Objectives
A clinical trial was conducted to measure and analyse the pharmacokinetic parameters of a lipid formulation of risperidone, VAL401. The VAL401 formulation is designed to repurpose risperidone from an antipsychotic to an adenocarcinoma treatment, with the lipid formulation altering the cellular uptake of risperidone, thus enabling anticancer biology to be exhibited in preclinical testing.
Methods
This first human trial of VAL401 measured the concentrations of risperidone and its primary metabolite, 9-hydroxyrisperidone, in the blood of patients after treatment with a single 2-mg dose of VAL401.
Results
The trial provided information on differences in the pharmacokinetic profile of risperidone in VAL401 that may be caused by the formulation and/or the nature of the cancer patient population. VAL401 provided the following key pharmacokinetic parameters for the risperidone plasma concentration after a single 2-mg dose of VAL401, with results normalised to a dosage of 1 mg for comparison with literature values: Tmax, 2 h; Cmax, 8 ng/ml; half-life, 3.5 h; area under the plasma concentration–time curve from time zero to infinity (AUC0–8), 58.2 ng h2/mL.
Conclusions
Further comparisons of the pharmacokinetic parameters of risperidone and 9-hydroxyrisperidone in plasma of patients administered VAL401 and the corresponding parameters obtained from published data for conventionally formulated risperidone provide evidence for altered biological processing of VAL401 as compared to risperidone. The absolute values obtained provide support for future studies of VAL401 as a cancer treatment, as the Cmax demonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
Afraid you will have to persevere, Im too busy at mo, to copy type... I think its called dyor ?
What does the neville report say please? Cant read it. TIA
Thanks Valju
Thanks.....I'll try again.
Fred, I went straight into it (not sure if by pure luck or if it was just clicking and reading) but was able to view online and t showed a great deal of information? To be honest a little tied up at work at the mo, for the reason I mentioned earlier.
Just applied for it....2 days wait, advised....can you share anything now?
Key points, you clearly wish us to read?
To, "All" read the neville registrar's report... and make you own minds up... ???
7 patients ? and you are trying to establish accurate data to generate a deal ? all for helping you out guys but
the algorithm is pretty simple
n7 = worthless
rather a sad comment there inanaco, considering the reference for 401 assisting with quality of life and is aimed at cancer sufferers ?
where as, fresh water aids all ?
further more the data can be read in detail if you peruse the Neville Registrar's website ? www.nevilleregistrars.co.uk and search Val 401
based on what data ? quality of life .. ? 401 .. tap water is good for quality of life ..
BP I think it is just frustration setting in for all of us - we just need some money from a deal to stop the rot. A few points: 1. The negotiations for 401 are being handled by the US rep company, not VAL directly or GM. 2.personally l think the presentations have always been good and like him or not, GM has always been candid in Q&A’s. 3. They will RNS 401 only when there is news. Saying discussions are ongoing is not NEWS, i.e. nothing new to say. 4. Regarding 401 negotiations, a card player never shows his hand unless he has won or lost. Don’t get me wrong BP, l’m on your side. Personally l think 401 talks are still ongoing but not finalised, but l’d love to be proved wrong as this could.
Afternoon Ladies/Gents, Tony, I also live in hope for the same outcome, I just don’t understand why they aren’t creating more a buzz around how fantastic there science is... GM may be a fantastic scientist, and I respect him for that. But he comes across very arrogant, and quite frankly boring. It’s like his get up and go has got up and f...cked off tbh. Turning up to investor evenings half prepared, comes across with next to zero enthusiasm. Put a glass eye to sleep for Christ sake. Uncanny, Sorry I disagree, there was nothing to stop them from updating the market on the 401 compound on the back that great rns regarding 201-301. We are still in very strong advanced stage discussions with possible future partners these are deals are extremely complexed bla bla bla. It’s been four months since GM mentioned it at the presentation evening in Scotland. Give us all some confidence, telling us how excited they are.. with future prospects. So if there is a “DEAL” they certainly seems they keep using a very strange business strategy to say least. GM in my opinion is not deal maker, we need someone at the helm with more direction, with a good business strategy to launch these amazing compounds into space. Something just doesn’t seem right in my opinion, I really hope I’m proved wrong for our sakes and sanity Lol. Make or break time now I’m afraid George. PS forkie, I do enjoy your sense of humour, I think wicked may be fitting discription, we need some humour on this board. GLA Cheers BP
Tommy85, how are you my good friend? I hope you're well.
Do you think we will see a massive volume this week?
Have a nice day, take care.
Obelix
I would agree Tony. We have heard that a deal will be concluded in Q1, if there was any news to the contrary surely we would have been informed. Could potentially be a big week! Fingers crossed. GL all
I thought I would cheer everyone up and trying to take my attention away from Brexit and Inept Politicians. I am hoping that not everyone who is Board Member of a PLC is not as insincere as a Politician.
We all hope you are right Tony
I think there will be an announcement relating to a 401 Deal this week, either it will be the deal or an update on its progress. If the BOD can keep any credibility it will be keeping its word when it forecast a deal would be concluded by the end of the first Quarter, if a deal was not going to happen you would think they would not leave it until the last minute to announce usually companies warn in advance such as profit warnings prior to results. It is without this kind of an update I am expecting some massive news this week on a 401 deal.
I'm sure she feels the same!!
Doesn't need any one individual to represent a company.....as no one's indespensable ...if Satu is attending the show....isn't she the most senior executive within company?
If she is, I'm looking forward to meeting her and listening to what she has to say!
Uncanny.....................Interesting Viewpoint...............................
"".Apart from the dilution which is eveyones gripe including mine, albeit little atlternative, what you have is 4 compounds that work of which 401 is a halt to constant refinancing and dilution and 201 is a game changer!
So actually things are good and what an entry level opportunity to invest!"""
George will be happy with that!!!! Anyone know why he has chosen not to share the end Q1 news with everyone at The Investor Show??
Blue Actually thats incorrect. There will be radio silence on 401 until a deal done /signed off. 201 and 301 was a regulatory requirement to update the market hence the RNS. Apart from the dilution which is eveyones gripe including mine, albeit little atlternative, what you have is 4 compounds that work of which 401 is a halt to constant refinancing and dilution and 201 is a game changer! So actually things are good and what an entry level opportunity to invest! Buying more at end of week. GLA